Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Predicción del fracaso del soporte ventilatorio no invasivo mediante monitorización no invasiva en pacientes no intubados con insuficiencia respiratoria hipoxémica aguda o insuficiencia posextubación. el estudio PREVISIÓN (PREVISION)

6 de noviembre de 2026 actualizado por: Unity Health Toronto

Predicción del fracaso del soporte ventilatorio no invasivo mediante monitorización no invasiva en pacientes no intubados con insuficiencia respiratoria hipoxémica aguda o insuficiencia posextubación: el estudio PREVISION

The goal of this observational study is to assess the potential non-invasive tools (e.g. regional ventilation, respiratory muscle response, lung mechanic's parameters) to identify the risk of failure when using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV).

The main question, it aims to answer is:

Does abnormal regional ventilation could predict HFNC or NIV failure?

Descripción general del estudio

Descripción detallada

This is a single-center, prospective, physiological study.

The study will enroll patient who has used either HFNC or NIV for the indications of 1. to prevent worsening acute hypoxemic respiratory failure or 2. to prevent reintubation. Once being confirmed to meet the inclusion criteria, the research team will apply the electrical impedance tomography (EIT) on the patient and start recording for 5-10 minutes as well as perform diaphragm and parasternal intercostal muscle ultrasound when the patient is using HFNC or NIV. The current HFNC or NIV setting, some lung mechanic's parameters (e.g. rapid shallow breathing trial (RSBI), negative airway pressure generated during the first 100 milisecond (P0.1), end-expiratory occlusion pressure(ΔPocc) derived from NIV machine), patient's characteristic, dyspnea scores (intensive care respiratory distress observation scale, IC-RDOS; work of breathing scale; self-report of dyspnea visual analog scale, D-VAS), ICU and hospital length of stay will be also collected.

The investigator will use EIT to visualize where air goes in the patient's lung and inspiratory muscle ultrasonography (diaphragm and parasternal intercostal muscle) to visualize the muscle activities when using HFNC or NIV. EIT is a measurement often used in the ICU since it allows easy visualization and is a non-invasive technique. The sensors measure electrical current changes during inspiration and expiration and will not cause any pain or radiation concerns. The EIT belt (3-cm diameter) will be placed around the chest without causing adverse event/discomfort/pain.

The duration of study will be approximately 30 minutes. The study will be conducted one time for one enrolled patient.

HFNC or NIV (device) failure is considered as either intubation/reintubation or death, whatever has come first. It will be followed up to 7 days.

The investigators will proceed with the measurements only with agreement from the clinical team. The investigators will analyze the data collected offline with a dedicated software afterwards.

After these study procedures are completed, data will also be collected from the participant's chart and combined with relevant information from the HFNC or NIV settings and vital functions. Confidentiality will be maintained throughout the entire study.

Tipo de estudio

De observación

Inscripción (Estimado)

80

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Ontario
      • Toronto, Ontario, Canadá, M5B 1W8
        • St. Michael's Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Patient who is using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV) to either prevent 1. intubation in the context of acute hypoxemic respiratory failure or 2. reintubation in the context of high risk group of extubation.

Descripción

Inclusion Criteria:

  • Age of ≥ 18 years
  • Using NIV or HFNC anywhere in the hospital

Exclusion Criteria:

  • Chronic CO2 retention
  • Neuromuscular disorder
  • Requiring home NIV (CPAP or BIPAP)
  • Tracheostomy
  • Contraindication to EIT placement: pacemaker/defibrillator implantation, burns at the area of EIT placement

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Difference in regional ventilation distribution (%)
Periodo de tiempo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.

The primary endpoint is to assess regional ventilation distribution (%) when using HFNC or NIV to predict a device failure.

The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Diaphragm or parasternal intercostal muscle thickening fraction
Periodo de tiempo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.

To assess ultrasound measurement of inspiratory muscle activity when using HFNC or NIV to predict a device failure.

The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
Rapid shallow breathing index (RSBI) in mL/breaths/min
Periodo de tiempo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.

To assess non-invasive respiratory - rapid shallow breathing index (RSBI) derived from NIV to predict a device failure.

The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
Respiratory drive using negative airway pressure generated during the first 100 millisecond (P0.1)
Periodo de tiempo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.

To assess respiratory drive - using negative airway pressure generated during the first 100 millisecond (P0.1) in cmH2O to predict device failure.

The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
Respiratory effort using end-expiratory airway occlusion pressure (ΔPocc)
Periodo de tiempo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.

To assess respiratory effort using end-expiratory airway occlusion pressure (ΔPocc) in cmH2O to predict device failure

The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
The intensive care respiratory distress observation scale (IC-RDOS)
Periodo de tiempo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.

To assess the level of dyspnea using intensive care respiratory distress observation scale (IC-RDOS) to predict a device failure. There is no minimum or maximum range depending on patient's heart rate, the higher score means worse outcome. When the score ≥ 2.4, it likely indicates clinically important dyspnea requiring clinical management.

The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
The work of breathing scale
Periodo de tiempo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.

To assess the work of breathing scale to predict a device failure. Minimum is 3 and maximum is 12, the higher score means worse outcome. When the score > 4, it likely indicates severe respiratory distress.

The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
Self-report of dyspnea visual analog scale (D-VAS)
Periodo de tiempo: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.

To assess self-report of dyspnea visual analog scale (D-VAS) to predict a device failure. Minimum is 0 and maximum is 10, the higher score means worse outcome. When the score > 3, it likely indicates dyspnea and being used for quality of palliative care unit

The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

27 de enero de 2025

Finalización primaria (Estimado)

1 de junio de 2027

Finalización del estudio (Estimado)

1 de junio de 2027

Fechas de registro del estudio

Enviado por primera vez

25 de noviembre de 2024

Primero enviado que cumplió con los criterios de control de calidad

28 de noviembre de 2024

Publicado por primera vez (Actual)

4 de diciembre de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

10 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir